Sanofi: agreement for acquisition of Synthorx
(CercleFinance.com) - Sanofi has announced that it has reached a final agreement with Synthorx to acquire all of its shares in issue at a price of 68 dollars per share, in a cash deal worth approximately 2.
5 billion dollars.
The "Lead asset THOR-707 ("not-alpha" IL-2) being explored across multiple solid tumor types alone and in combination with immune checkpoint inhibitors and other future IO combinations," Sanofi said.
The group plans to finance this transaction with its free cash flow. The takeover bid is due to begin in December 2019 and is subject to various conditions, with its completion expected in Q1 2020.
Copyright (c) 2019 CercleFinance.com. All rights reserved.